Aethlon Medical, Inc. (OTCBB:AEMD) announced today that the Hemopurifier(TM), a medical device developed to treat drug and vaccine resistant pathogens, was presented as a candidate treatment for drug resistant HIV patients at The AIDS Institute’s Treatment Horizons Forum held in conjunction with the XVI International AIDS Conference in Toronto, Canada. The Treatment Horizons Forum provides the medical, scientific, and HIV-infected community the opportunity to learn about promising new developments in HIV/AIDS research. Aethlon Chairman and CEO James A. Joyce gave the presentation. Mr. Joyce has accepted a second invitation from The AIDS Institute to present at 8 pm EST this evening at the AIDS Global Village located in the Metro Toronto Convention Centre, host site of the XVI International AIDS Conference.
